GSK settles Zantac suit before trial

GSK reached a settlement for another US lawsuit claiming the drugmaker’s blockbuster heartburn medication Zantac causes cancer. The UK pharmaceutical company didn’t disclose the value of the settlement in a statement Wednesday. The case, which was scheduled to begin trial in California state court on Nov. 13, will be dismissed, it said. A number of former Zantac users have sued GSK after the drug was found in 2019 to contain a probable carcinogen called NDMA. The US Food and Drug Administration forced Zantac and its generic versions off the market in 2020 after determining that NDMA hadn’t been introduced into the drug, but formed in the medication itself, either during storage or at elevated temperatures.